THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS

被引：0
|
作者：
Garcia-Perez, L. E. [1 ]
Sapin, H. [2 ]
Norrbacka, K. [3 ]
Guerci, B. [4 ]
Giorgino, F. [5 ]
Aigner, U. [6 ]
Federici, Orsini M. [7 ]
Gentilella, R. [7 ]
Heitmann, E. [8 ]
Jung, H. [8 ]
Rosilio, M. [2 ]
Boye, K. [9 ]
机构：
[1] Lilly SA, Alcobendas, Spain
[2] Lilly France SAS, Neuilly Sur Seine, France
[3] Eli Lilly & Co, Helsinki, Finland
[4] CHRU Nancy, Hop Brabois Adultes, Nancy, France
[5] Univ Bari Aldo Moro, Bari, Italy
[6] Versdias GmbH, Sulzbach Rosenberg, Germany
[7] Eli Lilly Co Italia SpA, Florence, Italy
[8] Lilly Deutschland GmbH, Bad Homburg, Germany
[9] Eli Lilly & Co, Greenwood, IN USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB116
引用
收藏
页码：S593 / S593
页数：1
相关论文
共 50 条
  • [1] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
    Luis-Emilio García-Pérez
    Kristina S. Boye
    Myriam Rosilio
    Heike Jung
    Elke Heitmann
    Kirsi Norrbacka
    Marco Orsini Federici
    Raffaella Gentilella
    Bruno Guerci
    Francesco Giorgino
    Ulrich Aigner
    Hélène Sapin
    [J]. Diabetes Therapy, 2021, 12 : 1929 - 1946
  • [2] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
    Garcia-Perez, Luis-Emilio
    Boye, Kristina S.
    Rosilio, Myriam
    Jung, Heike
    Heitmann, Elke
    Norrbacka, Kirsi
    Federici, Marco Orsini
    Gentilella, Raffaella
    Guerci, Bruno
    Giorgino, Francesco
    Aigner, Ulrich
    Sapin, Helene
    [J]. DIABETES THERAPY, 2021, 12 (07) : 1929 - 1946
  • [3] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS
    Sapin, H.
    Garcia-Perez, L. E.
    Norrbacka, K.
    Giorgino, F.
    Guerci, B.
    Aigner, U.
    Federici, Orsini M.
    Gentilella, R.
    Heitmann, E.
    Jung, H.
    Rosilio, M.
    Boye, K.
    [J]. VALUE IN HEALTH, 2019, 22 : S588 - S588
  • [4] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
    Boye, Kristina S.
    Sapin, Helene
    Garcia-Perez, Luis-Emilio
    Rosilio, Myriam
    Orsini Federici, Marco
    Heitmann, Elke
    Jung, Heike
    Aigner, Ulrich
    Guerci, Bruno
    Giorgino, Francesco
    Norrbacka, Kirsi
    [J]. DIABETES THERAPY, 2020, 11 (10) : 2383 - 2399
  • [5] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE
    Boye, K.
    Garcia-Perez, L. E.
    Sapin, H.
    Rosilio, M.
    Federici, Orsini M.
    Heitmann, E.
    Jung, H.
    Gentilella, R.
    Aigner, U.
    Guerci, B.
    Giorgino, F.
    Norrbacka, K.
    [J]. VALUE IN HEALTH, 2019, 22 : S593 - S593
  • [6] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
    Kristina S. Boye
    Hélène Sapin
    Luis-Emilio García-Pérez
    Myriam Rosilio
    Marco Orsini Federici
    Elke Heitmann
    Heike Jung
    Ulrich Aigner
    Bruno Guerci
    Francesco Giorgino
    Kirsi Norrbacka
    [J]. Diabetes Therapy, 2020, 11 : 2383 - 2399
  • [7] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis
    Guerci, Bruno
    Giorgino, Francesco
    Garcia, Luis-Emilio
    Boye, Kristina
    Norrbacka, Kirsi
    Sapin, Helene
    Heitmann, Elke
    Lebrec, Jeremie
    Dib, Anne
    Federici, Marco O. Orsini
    [J]. DIABETES, 2021, 70
  • [8] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT REPORTED OUTCOMES AT 12-MONTHS
    Boye, K.
    Lebrec, J.
    Sapin, H.
    Guerci, B.
    Giorgino, F.
    Fuechtenbusch, M.
    Heitmann, E.
    Federici, Orsini M.
    Dib, A.
    Garcia-Perez, L. E.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S242 - S242
  • [9] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): 6-MONTH ANALYSIS RESULTS
    Giorgino, F.
    Guerci, B.
    Garcia-Perez, L. E.
    Boye, K.
    Aigner, U.
    Heitmann, E.
    Federici, Orsini M.
    Zimner-Rapuch, S.
    Rosilio, M.
    Norrbacka, K.
    Sapin, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S506 - S506
  • [10] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months
    Boye, Kristina S.
    Lebrec, Jeremie
    Dib, Anne
    Heitmann, Elke
    Federici, Marco Orsini
    Yu, Maria
    Sapin, Helene
    Barrett, Annabel
    Guerci, Bruno
    Giorgino, Francesco
    Fuechtenbusch, Martin
    Garcia-Perez, Luis-Emilio
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3453 - 3464
12345